FLII

FLII (Flightless I) is a multidomain actin-remodeling protein and transcriptional coregulator that couples cytoskeletal dynamics to signaling at the actin cytoskeleton, the nucleus, and the plasma membrane (PMID:9177775, PMID:10092519). Its bipartite architecture combines an N-terminal leucine-rich repeat (LRR) domain with a C-terminal gelsolin-like actin-binding domain (PMID:9177775); the gelsolin-like domain binds G-actin and F-actin and severs filaments in a Ca2+-independent manner, while the LRR domain directly binds activated Ras with high affinity and suppresses activated-RAS phenotypes (PMID:10092519). In the nucleus, FLII acts as a transcriptional coregulator that inhibits beta-catenin/LEF1-dependent transcription, disrupting the synergy between its activating partner FLAP1, p300, and beta-catenin, thereby negatively regulating Wnt/beta-catenin signaling (PMID:16990252). At the cell periphery, FLII interacts with activated Rac1 and drives pro-migratory cytoskeletal remodeling downstream of the GEF P-Rex1 in a RhoA/ROCK-independent fashion (PMID:26887924). FLII also modulates skin and dermal integrity through interplay with TGF-beta1–Smad signaling, where its expression level controls blistering severity, integrin and collagen VII production, and fibroblast collagen gel contraction (PMID:21984127).

1. 1997 Medium

   Establishing the human gene's domain architecture defined FLII as a candidate dual-function protein bridging signaling and the cytoskeleton, before any biochemical activity was known.

   Evidence cDNA cloning, sequencing, and Northern blot expression analysis identifying an LRR domain, a gelsolin-like domain, and muscle-enriched expression

   PMID:9177775

   Open questions at the time

   • Domain activities inferred from sequence homology, not biochemically reconstituted
   • Functional consequence of muscle-enriched expression not tested
2. 1999 High

   Direct biochemical assignment of activity to each domain showed the LRR binds activated Ras and the gelsolin-like domain severs actin, defining FLII as a physical link between Ras signaling and actin remodeling.

   Evidence In vitro Kd binding measurement, yeast genetic suppression of activated RAS2, and in vitro actin-binding/severing assays on the C. elegans ortholog FLI-1

   PMID:10092519

   Open questions at the time

   • Performed on the C. elegans ortholog; conservation of activity in human FLII inferred
   • Cellular consequence of Ras binding not established
3. 2006 Medium

   Identifying FLII as a transcriptional coregulator extended its role from the cytoskeleton into nuclear control of Wnt/beta-catenin signaling.

   Evidence Co-immunoprecipitation, reporter transcription assays, and siRNA knockdown of FLAP1 mapping FLII as an inhibitor of beta-catenin/LEF1 transcription opposed by FLAP1

   PMID:16990252

   Open questions at the time

   • Mechanism of FLII nuclear recruitment to target promoters not defined
   • Single-lab interaction mapping without orthogonal structural validation
4. 2011 Medium

   Genetic gain- and loss-of-function in a skin blistering model linked FLII expression level to dermal integrity through TGF-beta1–Smad signaling.

   Evidence Murine Flii allele crosses with a collagen VII epidermolysis bullosa model, fibroblast collagen gel contraction assays, immunohistochemistry, and Western blot

   PMID:21984127

   Open questions at the time

   • Direct molecular link between FLII and the TGF-beta1–Smad pathway not biochemically resolved
   • Whether the actin or transcriptional activity of FLII drives the skin phenotype not separated
5. 2016 High

   Identifying FLII as a Rac1 effector placed it in a specific GEF-defined migratory pathway, distinguishing its cytoskeletal role from generic RhoA/ROCK contraction.

   Evidence Mass spectrometry Rac1 interactome, reciprocal Co-IP, siRNA migration assays, and pharmacological inhibition establishing P-Rex1–Rac1–FLII pro-migratory signaling

   PMID:26887924

   Open questions at the time

   • Structural basis of the Rac1–FLII interaction not resolved
   • Whether actin severing by the gelsolin domain executes the migratory phenotype not directly tested

• How FLII integrates its actin-severing, small-GTPase-binding, and transcriptional coregulatory activities into a unified cellular program remains unresolved.
• No structural model coupling LRR GTPase binding to gelsolin-domain actin severing
• Mechanism of nuclear/cytoplasmic partitioning between transcriptional and cytoskeletal roles unknown